| Prev Close | 198.22 |
| Open | 197.85 |
| Day Low/High | 197.85 / 200.75 |
| 52 Wk Low/High | 90.57 / 213.94 |
| Volume | 444.39K |
Seagen, Inc. (SGEN)
198.02
0.20
0.10
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 174.00B |
| Market Cap | 34.96B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
The Trader Daily
The $193 level on the SPY will be key today.
The Trader Daily
Thursday's SPY trade plan will involve fading the edges,
What Makes a Bull Market?
You're looking at one.
Jim Cramer Says Keep an Eye on 'New Pharma' as an Investment Theme
TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.
Timing It Right in this Market (Part 2)
For these kinds of growth stocks, you have no choice but to wait.
Timing It Right in this Market (Part 1)
Here are some specific stocks working as parables right now.
Seductive Words of the Fisherman Skeptic
It's sardonic, corroded commentary designed to keep your pole in the boat.
This Froth Has to Be Reined In
The public market is currently divorced from the dazzling IPOs -- and that's always a bad sign.
Earnings Roundup
Here is my compilation of last night's profit reports. 24 beats: W&T Offshore (WTI) Oasis Petroleum (OAS) Marathon Oil (MRO) Huntington Ingalls Industries (HII) Cognizant Technology Solutions (CTSH) Disney (DIS) Electronic Arts (EA) Regency Centers ...
The Next Big Thing in Biotech: M&A
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.
